ROSEN, TOP RANKED GLOBAL COUNSEL, Encourages Akebia Therapeutics, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action - AKBAPRNewsWire • 03/30/22
Akebia Therapeutics Receives Complete Response Letter from the FDA for Vadadustat for the Treatment of Anemia due to Chronic Kidney Disease in Adult PatientsPRNewsWire • 03/30/22
ROSEN, RESPECTED INVESTOR COUNSEL, Encourages Akebia Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - AKBANewsfile Corp • 03/29/22
ROSEN, A TOP RANKED LAW FIRM, Encourages Akebia Therapeutics, Inc. Investors with Losses Over $100K to Secure Counsel Before Important Deadline in Securities Class Action - AKBANewsfile Corp • 03/25/22
AKEBIA THERAPEUTICS, INC. CLASS ACTION ALERT: Wolf Haldenstein Adler Freeman & Herz LLP announces that a securities class action lawsuit has been filed in the United States District Court for the Eastern District of New York against Akebia Therapeutics, IPRNewsWire • 03/24/22
ROSEN, TRUSTED AND TOP RANKED INVESTOR COUNSEL, Encourages Akebia Therapeutics, Inc. Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action - AKBAPRNewsWire • 03/23/22
AKBA LOSS ALERT: ROSEN, NATIONAL INVESTOR COUNSEL, Encourages Akebia Therapeutics, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action - AKBANewsfile Corp • 03/22/22
Bronstein, Gewirtz & Grossman, LLC Notifies Akebia Therapeutics, Inc. (AKBA) Shareholders of Class Action and Encourages Investors to Contact the FirmBusiness Wire • 03/22/22
ROSEN, A LEADING LAW FIRM, Encourages Akebia Therapeutics, Inc. Investors With Losses to Secure Counsel Before Important Deadline in Securities Class Action – AKBABusiness Wire • 03/21/22
AKEBIA ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against Akebia Therapeutics, Inc. and Encourages Investors to Contact the FirmBusiness Wire • 03/18/22
AKBA EQUITY ALERT: ROSEN, A LEADING LAW FIRM, Encourages Akebia Therapeutics, Inc. Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action - AKBAPRNewsWire • 03/16/22
SHAREHOLDER ALERT: Holzer & Holzer Announces a Class Action Was Filed on Behalf of Akebia Investors (AKBA) and Encourages Investors With Significant Losses to Contact the FirmNewsfile Corp • 03/15/22
AKEBIA THERAPEUTICS, INC. (NASDAQ: AKBA) SHAREHOLDER CLASS ACTION ALERT: Bernstein Liebhard LLP Announces that a Securities Class Action Lawsuit Has Been Filed Against Akebia Therapeutics, Inc. (NASDAQ: AKBA)PRNewsWire • 03/15/22
AKBA EQUITY ALERT: ROSEN, A TOP RANKED LAW FIRM, Encourages Akebia Therapeutics, Inc. Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action – AKBABusiness Wire • 03/15/22
Akebia Therapeutics Reports Fourth Quarter and Full-Year 2021 Financial Results and Recent Business HighlightsPRNewsWire • 03/01/22
Akebia Therapeutics Announces Amendment of License Agreement with Vifor Pharma in Preparation for Potential Vadadustat LaunchPRNewsWire • 02/22/22
Akebia Therapeutics to Report Fourth Quarter and Full-Year 2021 Financial Results and Discuss Recent Business HighlightsPRNewsWire • 02/09/22
Bronstein, Gewirtz & Grossman, LLC Notifies Shareholders of Akebia Therapeutics, Inc. (AKBA) InvestigationBusiness Wire • 01/27/22
